Abingworth — Full Portfolio
54 tracked investments · listed companies and verified rows first
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.
BiotechHealthtechRedwood City, US
Judith Shizuru(Director)Herb Cross(Executive Officer)inJeet Mahal(Executive Officer, Director)inPatrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)
Board seatKurt von Emster· per SEC Form D · $132M raise · filed Aug 2026
Co-investorsAvego BioScience CapitalTSVCIkarian Capital
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)inDylan Hartley(Executive Officer)inWendy Johnson(Executive Officer)Nicholas A. Saccomano(President and Chief Executive Officer and Director)
BoardIsaac Manke(Director)in
Board seatBali Muralidhar· per SEC Form D
Co-investorsAccess BiotechnologyBoulder VenturesRiverVest Venture PartnersACORN BIOVENTURESNew Enterprise Associates (NEA)Novo Holdings
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)inSamir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg, M.D., M.P.H.(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)in
Board seatBali Muralidhar· per SEC Form D
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersNorwest Venture PartnersNovo HoldingsOmega Funds+1 more
BiotechSouth San Francisco, US
Grant E. Pickering(Chief Executive Officer)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)
Board seatKurt von Emster· per SEC Form D
Co-investorsCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesJanus Henderson InvestorsLongitude CapitalMedicxi+4 more
Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.
BiotechDigital HealthMedical DevicesSouth San Francisco, US
Marshall Fordyce(Executive Officer, Director)in
BoardBeth Seidenberg(Director)inMaha Katabi(Director)inPatrick Enright(Director)inAndrew Cheng(Director)
Board seatKurt von Emster· per SEC Form D
Co-investorsKleiner PerkinsLongitude CapitalSofinnova VenturesSofinnova Venture Partners
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+9 more
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inNeil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)inMichael Secora(Chief Financial Officer and Chief Corporate Development Officer)in
Co-investorsAscenta CapitalCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue ManagementEisai Innovation, Inc.+4 more
IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer.
BiotechHealthtechCambridge, US
Gary D. Glick(Founder)inH. Martin Seidel(Chief Executive Officer)in
BoardJean-Francois Formela(Director)in
Co-investorsAtlas Venture
Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.
BiotechHealthtechResearch Triangle Park, US
BT Slingsby(Co-Founder & Executive Chairman)in
Co-investorsCatalys PacificOrbiMedSamsara BioCapitalKB Investment
Redx is a clinical-stage biotechnology company developing small molecule targeted medicines focused on fibrotic diseases, leveraging ROCK pathway inhibitors and novel targets.
BiotechHealthtechMedical Devices
Lisa Anson(Chief Executive Officer)
BoardBernard Coulie(Independent Director)
Co-investorsREDMILEPerscitus LLP
Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.
AI & Machine LearningBiotechHealthtech
Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)inCourtney Beers(Chief Scientific Officer)
Co-investorsCanaan PartnersMPM BioImpactGilead SciencesAstellas Venture Management LLCLightstone Ventures
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Board seatBali Muralidhar· per SEC Form D
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomSV Health InvestorsTenmileAlly Bridge Group+2 more
GenSight Biologics develops clinical-stage gene therapy treatments, with a lead candidate (GS010/LUMEVOQ) in development for rare genetic diseases.
BiotechDigital HealthHealthtechMedical DevicesParis, FR
Jean-Philippe Combal(Executive Officer)Michael Stephen Wyzga(Director)Thomas Gidoin(Executive Officer)Didier Pruneau(Executive Officer)Florent Gros(Director)Nitza Thomasson(Executive Officer)
Board seatGenghis Lloyd-Harris· per SEC Form D · $25M raise · filed Jul 2015
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)inPeter Spargo(Executive Officer)inPatrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Board seatAndrew Sinclair· per SEC Form D · $200.2M raise · filed Jul 2020
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Board seatBali Muralidhar· per SEC Form D
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersFidelity InvestmentsIntermediate Capital Group+1 more
Abingworth is a venture capital and private equity firm specializing in life sciences and healthcare investments across seed, development, and clinical co-development stages.
BiotechHealthtechLondon, GB
Co-investorsModi Ventures
Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.
BiotechHealthtechSouth San Francisco, US
Kathleen Collins(Director)inLawrence Kong(Executive Officer)inRon Park(President & CEO)inFrancine Gregoire(Chief Scientific Officer)inPriya Parameswaran(Chief Business Officer)in
BoardJayson Punwani(Director)in
Co-investorsBEVCSR One Capital ManagementOsage University PartnersPivotal Life Sciences
Co-investorsAisling CapitalLYZZ CapitalRiverVest Venture Partners
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)in
Co-investorsAtlas VentureLightspeed Venture PartnersVida VenturesOmega FundsTenmileBiotechnology Value Fund
BiotechNewton Centre, US
Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)
BoardScott Minick(Director)inTodd T. Foley(Director)inVincent Miles(Director)Ansbert K. Gadicke(Director)in
Co-investorsHEALTHCARE ROYALTY PARTNERSSofinnova VenturesMPM BioImpact
CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.
BiotechDeep TechHealthtechZug, CH
Emmanuelle Charpentier(Co-founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJames R. Kasinger(General Counsel and Secretary)inStephen Kennedy(Head of Technical Operations)inMegan Wherry Menner(Head of Human Resources)inNaimish Patel(Chief Medical Officer)in
Co-investorsAvoro Capital AdvisorsNew Enterprise Associates (NEA)Versant Ventures
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.
BiotechHealthtechMedical DevicesNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)
BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in
Co-investorsAvoro Capital AdvisorsBay City CapitalForesite CapitalVantagePoint Capital Partners
Entact is a drug discovery company developing treatments for patients.
BiotechDeep TechWatertown, US
Victoria Richon(Executive Officer, Director, Promoter)inRuben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)Alon Lazarus(Director)
BoardAndrew Sinclair(Director)Anna French(Director)in
Co-investorsvenBio PartnersvenBio Global Strategic
BiotechCambridge, US
Magdalene Moran, Ph.D.(Executive Officer)Bert Chenard, Ph.D.(Executive Officer)Russell Herndon(Executive Officer, Director)Tom Burke(Executive Officer)
BoardVincent Miles(Director)Jean George(Director)
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Lilly Ventures
Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment.
BiotechMedical DevicesLondon, GB
Co-investorsBrandon Capital PartnersNovo HoldingsSofinnova Partners
Co-investors5AM VenturesAndera PartnersAngelini VenturesCDP Venture CapitalIndaco Venture PartnersM Ventures+1 more
Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy.
BiotechHealthtechAptos, US
Jason Levin(Founder, Director and Chief Executive Officer)Robert M. Myers(Executive Officer, Director)
BoardMichael Wasserman(Director)Patrick Enright(Director)inElisha (Terry) Gould(Director)Ernest Mario(Director)
Co-investorsH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude CapitalAdams Street PartnersAgent Capital
Co-investorsF-Prime Capital
Reneo is an asset and investment management platform for decarbonizing residential real estate portfolios in Germany.
Climate TechEnterprise SoftwarePropTechGermany, DE
Lennart Börner(Founder & Co-CEO)inAlexander Graubner-Müller(Founder & Co-CEO)in
Co-investorsFoundamentalAisling CapitalAmzak HealthEurazeoLakestarLundbeckfonden Ventures+4 more
Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Amzak HealthLundbeckfonden VenturesPappas CapitalRiverVest Venture Partners+1 more
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestVida Ventures+3 more
StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases.
BiotechHealthtechDurham, US
Aravind Asokan(Director)inMavis Abjandje-McKenna(Director)Richard Smith(Executive Officer)inPatrick Ritschel(Executive Officer, Director, Promoter)
Co-investorsPontifax Venture CapitalHatteras Venture Partners
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column Group+3 more
An Italian-language affiliate guide that reviews and ranks non-AAMS online casinos (foreign-licensed gambling sites) accessible to Italian players, comparing bonuses, game catalogs, payment methods, and licensing.
ConsumerGamingMedia & EntertainmentBridgewater, US
William Duke(Executive Officer)inKristine Peterson(Executive Officer, Director)
BoardDaniel Pelak(Director)Sean Traynor(Director)Ittai Harel(Director)inPaul Queally(Director)
Co-investorsAgate Medical Investments LPHLM Venture PartnersKaiser Permanente VenturesMPM BioImpactPitangoWelsh, Carson, Anderson & Stowe
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Allotera Therapeutics, Inc.CRISPR TherapeuticsIambic Therapeutics, Inc.Anjarium BiosciencesAscend Gene & Cell TherapiesAttenuaCytospire TherapeuticsGensight BiologicsGlycomineIFM TreLaunch TherapeuticsNido BiosciencesPixium VisionPrimeraDx (Primera Biosystems)Soleno TherapeuticsSynosia TherapeuticsSyntaxinVera TherapeuticsVirionHealthWilson Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.